Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Reuters

Feb 05

Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India

Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609306504"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609306504\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609306504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609306504","market":"fut","top_or_hot":-1,"title":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCo-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis <a href=\"https://laohu8.com/S/MTB\">$(MTB)$</a> and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CODX","symbol_name":"Co-Diagnostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLDfdBs:1","article_id":"2609306504","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609306504","pubTimestamp":1770300105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. , has received a license from the Central Drugs Standard Control Organization  to manufacture the CoSara PCR Pro real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis  and human papillomavirus , require separate regulatory clearance and are not yet available for sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CODX":"Co-Diagnostics, Inc.","BK4082":"医疗保健设备","BK4568":"美国抗疫概念"},"translate_title":"Co-Diagnostics合资企业CoSara获得CDSCO许可在印度生产PCR Pro仪器","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CODX":0.9},"content_text":"Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India\n    \n\n        Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis $(MTB)$ and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}